Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer

Future Oncol. 2019 Jan;15(2):105-107. doi: 10.2217/fon-2018-0086. Epub 2018 Nov 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Receptor, ErbB-2 / metabolism*
  • Receptors, Estrogen / metabolism*
  • Receptors, Progesterone / metabolism*
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Receptor, ErbB-2